reviewed april 2026|next review october 2026|88 physicians psi has verified|3745 published studies
Thymogen
Thymogen is a synthetic dipeptide (glutamyl-tryptophan) registered in Russia as an immunostimulatory medication, developed at the St. Petersburg Institute of Bioregulation and Gerontology as the structurally simplest peptide in the Khavinson bioregulator program.
Evidence landscape: 3745 published studies
3,745 published items. 11 human studies and 145 animal studies.
- 11 Human
- 145 Animal
- 44 Reviews
- 3545 Other research
Not FDA-approved. Registered as an immunostimulatory medication in Russia. No Western regulatory agency has approved thymogen. No Western-standard clinical trials have been conducted.
Available as nasal spray and injection in Russia. Not available through Western pharmaceutical channels. The compound is part of the Khavinson bioregulatory medicine program.
Thymogen (Glu-Trp) is the structurally simplest peptide in the Khavinson bioregulator program, consisting of just two amino acids. It is classified as a thymic bioregulator proposed to restore age-related immune decline through epigenetic gene modulation. The Khavinson program includes multiple organ-specific short peptides.
PSI Assessment
The Khavinson bioregulatory medicine program in St. Petersburg has produced a series of short peptides claimed to restore organ-specific function during aging. Thymogen is the simplest of these: a dipeptide consisting of just two amino acids (Glu-Trp), registered in Russia as an immunostimulant for secondary immunodeficiency. It has been used clinically in Russia for over two decades as a nasal spray and injection. The scientific claim that a 2-amino-acid peptide can selectively modulate thymic gene expression is ambitious. The evidence comes predominantly from a single research institute. No independent Western replication exists, and no Western-standard randomized controlled trials have been conducted.
Just two amino acids. Registered in Russia as an immunostimulant. The simplest peptide in the Khavinson bioregulator program. No independent Western replication.
The proposed mechanism is thymic peptide signaling restoration through epigenetic gene modulation. As a dipeptide (Glu-Trp), thymogen is the structurally simplest compound in the Khavinson program. Russian clinical data reports immune-stimulating effects in patients with secondary immunodeficiency. Available as nasal spray and injection in Russia. The Khavinson hypothesis that a 2-amino-acid peptide can selectively modulate thymic gene expression is scientifically ambitious.
What the evidence supports
Thymogen is registered as an immunostimulatory medication in Russia with clinical use spanning over two decades. Russian studies report immune function improvement in secondary immunodeficiency. The dipeptide structure (Glu-Trp) is the simplest in the Khavinson bioregulator program.
What is not yet established
Whether thymogen produces immunostimulatory effects by Western randomized controlled trial standards. Independent replication outside the St. Petersburg Institute. Whether a dipeptide can selectively modulate thymic gene expression as proposed. Comparative efficacy against established immune modulators.
Research Evidence
The findings below cover thymogen's Russian clinical use, the proposed mechanism, and the evidence limitations.
Evidence by condition
Evidence dimensions available for each condition Thymogen has been studied for.
| Condition | Mechanism | Animal evidence | Human evidence | Replication |
|---|---|---|---|---|
| Secondary Immunodeficiency | ||||
| Postoperative Recovery | ||||
| Chronic Infection Support |
Thymogen is registered as an immunostimulatory medication in Russia with reported clinical use spanning over two decades. Russian studies report improved immune parameters in patients with secondary immunodeficiency.
The clinical data comes predominantly from the St. Petersburg Institute of Bioregulation and Gerontology. Independent replication by Western research groups has not been published.
11 Human|145 Animal|44 Reviews
View all 3745 indexed studiesHow Thymogen Works
Thymogen (Glu-Trp) is a synthetic dipeptide from the Khavinson bioregulatory program. The proposed mechanism is epigenetic modulation of immune-related gene expression at the chromatin level. The claim that a dipeptide can achieve tissue-specific gene regulation through direct DNA interaction has not been independently validated.
A two-amino-acid peptide proposed to restore thymic immune function through gene modulation.
For a more detailed view of the biology, here is what researchers have observed at the molecular level.
Glu-Trp dipeptide. Proposed to modulate immune-related gene expression through epigenetic mechanisms. Data from the Khavinson laboratory in St. Petersburg.
What is Thymogen being studied for?
Researchers are studying Thymogen across several health conditions. Each condition below is labeled with the strength of evidence that exists for that specific use, not for Thymogen overall. This means a compound can have human studies for one condition but only animal data for another.
Secondary Immunodeficiency
·Human TrialsThymogen is registered in Russia for secondary immunodeficiency with clinical use spanning over two decades. Russian studies report improved T-cell parameters and clinical outcomes.
Limitations: No Western-standard randomized controlled trials. Evidence comes predominantly from a single research institute. Independent replication has not been published.
Postoperative Recovery
·Animal StudiesRussian clinical reports describe immune parameter improvement in postoperative patients treated with thymogen.
Limitations: Study designs do not meet current Western clinical trial standards. Sample sizes are generally small.
Chronic Infection Support
·Animal StudiesRussian data reports immune function support in the context of chronic infections. The proposed mechanism is restoration of T-cell mediated immunity.
Limitations: No independent Western validation. Whether the reported immune parameter changes translate to clinical infection outcomes is not established.
Safety and Regulatory Status
FDA Status: Not FDA-approved. Registered as an immunostimulatory medication in Russia. No Western regulatory review.
Availability: Available in Russia as nasal spray and injection. Not available through Western pharmaceutical channels.
Class context: Thymogen is a Khavinson bioregulator dipeptide (Glu-Trp). Russian clinical use history spans over two decades. Independent safety assessment by Western standards is limited.
Thymogen has been used clinically in Russia for over two decades with no significant safety concerns reported in Russian literature. Independent Western safety assessment has not been conducted.
Questions and Comparisons
Questions the evidence raises for a Thymogen discussion.
Comparison and Related Research
Thymogen is part of the Khavinson bioregulatory program. The comparisons below clarify its position relative to other thymic peptides and sister compounds.
Related compounds
Frequently Asked Questions
References
Each citation links to the original study on PubMed, the U.S. National Library of Medicine database.
- 1.A review of the Khavinson-Morozov program on thymic peptide bioregulators, covering the extraction of thymalin from calf thymus and the development of synthetic analogs including thymogen (Glu-Trp). The paper summarized clinical experience with thymalin in immunodeficiency states across Russian clinical settings.Morozov VG & Khavinson VKh, 1997 in Int J Immunopharmacol. View on PubMed
- 2.A long-term clinical observation study reporting that elderly patients treated with thymalin and epithalamin over multiple years showed reduced mortality rates compared to untreated controls. The authors proposed that periodic administration of thymic and pineal peptides could support immune function during aging.Khavinson VKh et al., 2003 in Neuro Endocrinol Lett. View on PubMed
- 3.A systematic review cataloguing evidence that short peptides, including thymic bioregulators, interact with DNA and regulate gene expression. The review covered in vitro, animal, and limited clinical data supporting epigenetic mechanisms of action for peptides in the Khavinson bioregulatory framework.Khavinson VK et al., 2021 in Molecules. View on PubMed
- 4.The second part of a two-part review summarizing clinical studies with peptide bioregulators including thymalin and thymogen. The paper reported outcomes from trials in elderly patients with various age-related conditions, documenting improvements in immune markers and mortality endpoints.Khavinson VKh, 2013 in Adv Gerontol. View on PubMed
Medical Disclaimer
This content is for educational and informational purposes only and does not constitute medical advice. The information presented reflects published research as indexed by PSI and should not be used to make treatment decisions. Always consult a qualified healthcare provider before starting, stopping, or modifying any treatment.